Strategic Investment Advisors MI Purchases 2,662 Shares of Amgen Inc. $AMGN

Strategic Investment Advisors MI raised its position in Amgen Inc. (NASDAQ:AMGN) by 50.0% during the first quarter, Holdings Channel.com reports. The institutional investor owned 7,986 shares of the medical research company’s stock after purchasing an additional 2,662 shares during the quarter. Strategic Investment Advisors MI’s holdings in Amgen were worth $2,810,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in AMGN. Ashton Thomas Securities LLC grew its position in Amgen by 15.6% during the 1st quarter. Ashton Thomas Securities LLC now owns 1,179 shares of the medical research company’s stock worth $415,000 after acquiring an additional 159 shares during the last quarter. Sunbelt Securities Inc. raised its position in Amgen by 1.5% in the 1st quarter. Sunbelt Securities Inc. now owns 7,658 shares of the medical research company’s stock valued at $2,694,000 after purchasing an additional 112 shares during the last quarter. Parvin Asset Management LLC raised its position in Amgen by 1.7% in the 1st quarter. Parvin Asset Management LLC now owns 5,739 shares of the medical research company’s stock valued at $2,019,000 after purchasing an additional 95 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Amgen by 0.7% in the first quarter. EverSource Wealth Advisors LLC now owns 19,686 shares of the medical research company’s stock worth $6,927,000 after purchasing an additional 131 shares in the last quarter. Finally, Empire Financial Management Company LLC boosted its stake in Amgen by 2.5% in the first quarter. Empire Financial Management Company LLC now owns 10,406 shares of the medical research company’s stock worth $3,661,000 after purchasing an additional 254 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Stock Down 1.4%

Shares of NASDAQ AMGN opened at $387.64 on Thursday. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $398.00. The firm’s 50-day moving average is $354.68 and its 200-day moving average is $353.11. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $209.21 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 3.98 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the firm posted $4.90 earnings per share. Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. Equities analysts expect that Amgen Inc. will post 22.31 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Morgan Stanley lowered their target price on Amgen from $340.00 to $333.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 8th. Barclays upped their price target on shares of Amgen from $350.00 to $360.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Argus decreased their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, May 20th. Mizuho raised their price objective on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday, June 16th. Finally, Truist Financial boosted their target price on shares of Amgen from $327.00 to $340.00 and gave the stock a “hold” rating in a research note on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average price target of $357.00.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s monthly weight-loss drug remains a potentially significant long-term catalyst, with six Phase 3 trials underway. Success could give the company an opportunity to compete with Eli Lilly and Novo Nordisk in the fast-growing obesity-treatment market. Watch Out, Eli Lilly and Novo Nordisk: Amgen’s Monthly Weight Loss Drug Has 6 Phase 3 Trials Running
• Neutral Sentiment: Amgen will report second-quarter 2026 results after the market close on August 4, followed by a conference call with management. The event is the next major catalyst for the stock, particularly for updates on earnings, guidance and the obesity-drug program. Amgen Announces Webcast of 2026 Second Quarter Financial Results
• Negative Sentiment: Analysts cited a weaker setup for Amgen’s second-quarter report, with earnings expected to decline and the company lacking the indicators typically associated with a likely earnings beat. This may be pressuring the shares ahead of the results. Earnings Preview: Amgen Q2 Earnings Expected to Decline
• Negative Sentiment: Barclays raised its Amgen price target to $360 from $350 but maintained an “equal weight” rating. Because the target remains below the stock’s recent trading level, the call signals limited near-term upside and valuation caution. Barclays Raises Amgen Price Target
• Negative Sentiment: Despite the obesity opportunity, analysis also questions whether Amgen’s candidate will be competitive enough to capture meaningful market share. That uncertainty increases the risk surrounding the company’s long-term growth strategy. Amgen Weight-Loss Drug Competition Analysis

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.